FDA Advisory Committee Unanimously Recommends Approval of Dalvance(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
March 31, 2014 17:09 ET
|
Durata Therapeutics, Inc.
CHICAGO, March 31, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) announced today that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted 12...
Durata Therapeutics, Inc. Reports Fourth Quarter and Full-Year 2013 Financial Results
March 14, 2014 07:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, March 14, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced its fourth quarter and full year 2013 financial results.
"2013 was a year of incredible...
Durata Therapeutics to Announce Full Year 2013 Financial Results on March 14, 2014
March 07, 2014 08:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, March 7, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly conference call for Friday, March 14th at 8:30 a.m. Eastern Time to discuss fourth quarter/full...
Durata Therapeutics to Present at Upcoming Investor Conferences
March 03, 2014 08:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, March 3, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that the members of the management team will make presentations at two upcoming...
Durata Therapeutics to Present at the RBC Capital Markets' Global Healthcare Conference
February 18, 2014 08:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, Feb. 18, 2014 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the 2014 RBC Capital Markets' Global...
European Medicines Agency Accepts Marketing Authorization Application for Dalbavancin
December 23, 2013 08:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, Dec. 23, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that the European Medicines Agency (EMA) has accepted for review a Marketing Authorization...
Durata Therapeutics Submits Marketing Authorization Application for Dalbavancin
December 03, 2013 08:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, Dec. 3, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency...
Durata Therapeutics Announces FDA's Acceptance for Priority Review of NDA for Dalvance(TM) (dalbavancin hydrochloride)
November 26, 2013 16:15 ET
|
Durata Therapeutics, Inc.
CHICAGO, Nov. 26, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that the New Drug Application (NDA) for its investigational drug, Dalvance™ (dalbavancin...
Durata Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
November 15, 2013 16:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, Nov. 15, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) announced today that Paul R. Edick, CEO, will present an overview of the Company at the Jefferies 2013 Global Healthcare...
Durata Therapeutics, Inc. Reports Third Quarter 2013 Financial Results
November 06, 2013 06:00 ET
|
Durata Therapeutics, Inc.
CHICAGO, Nov. 6, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the quarter ended September 30, 2013.
Financial results for the quarter ended...